SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
CYTX Analysis & Videos »
CYTX: Bull or Bear?
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
CYTX
|
|
|
+15.86%
in
7 days
On 11/16/09, Cytori Therapeutics (NASDAQ: CYTX) completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium on 12/12/0 at 7am (CT) by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary. ...
|
BioMed News Bytes: Cytori (NASDAQ: CYTX), Questcor (NASDAQ: QCOR)
CYTX
|
|
|
-0.53%
in
31 days
(closed on 11/16/09)
Cytori Therapeutics (NASDAQ: CYTX) sent out an email alert to investors on 10/15/09 in the evening pertaining to results that were presented at the 7th Annual Meeting of the International Federation for Adipose Therapeutics and Science (IFATS) that demonstrated the safety and feasibility of using a patient’s own adipose-derived stem and regenerative cells (ADRCs) processed by Cytori’s Celution 800 System to treat stress urinary incontinence (SUI) in a five patient pilot study conducted in Japan. <> <> <font> <>http://www.mikehavrx.com/2009/10/biomed-news-bytes-cytori-nas....
|
FDA Calendar Extreme Trades: 85 Single Digit Stocks
CYTX
|
|
|
+7.47%
in
3 days
(closed on 10/16/09)
<> <> The <font> BioMedReports.com FDA Calendar database </font> includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results. My FDA Calendar Extreme Trades article series highlights companies with market caps below $1 billion and / or single digit stock prices with pending catalysts in the form of FDA decisions, clinical trial res...
|
Cytori’s Cardiac Celution: Encouraging Interim Data (NASDAQ: CYTX)
CYTX
|
|
|
-8.04%
in
10 days
(closed on 10/03/09)
In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction (MI, heart attack) and chronic myocardial ischemia (a severe form of coronary artery disease) with modes of action that include would remodeling, neo-angiogenesis (new blood vessel formation), anti-apoptosis (preventing the process of programmed cell death), immune modulation, and beneficial signaling mechanisms between cells. <o:p> </o:p> <o:p> </o:p> ...
|
Stem Cell Index Surges in Past Week
CYTX
|
|
|
+51.20%
in
127 days
(closed on 09/14/09)
<> The stem cell trade was back in a big way over the past week, with several stocks in the <font> ETF Innovators Stem Cell Index </font> registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P Biotech (NYSE:XBI +4%). Hot stocks over the past week among the 40 component companies in the stem cell index include NeoStem (AMEX:NBS) +52.2%, Cytori Therapeutics (NASDAQ:CYTX) +37%, and Geron (NASDAQ:GERN) +22%. Two other widely followed stocks from the index registered smaller gains,...
|
Cytori Therapeutics: Stock Profile and 2009 Outlook
CYTX
|
|
|
-7.65%
in
26 days
(closed on 04/09/09)
<> 
Cytori Therapeutics (CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types. The Company develops and markets cell banking, therapeutic, and cosmetic medicine applications for its Celution System, which enables real-time regenerative cell therapy applications by harvesting and processing a small amount of patient-derived fat tissue in about one hour to harvest the adipose-derived stem and regenerative cells (ADRCs).
...
|
Analysis of Global Stem Cell Index YTD
CYTX
|
|
|
-7.89%
in
6 days
(closed on 03/10/09)
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index , which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). <> Below is a profile for each company, including a summary of their b...
|
Cytori Therapeutics: A Natural Play on Cosmetic Medicine
CYTX
|
|
|
-17.39%
in
3 days
(closed on 03/04/09)
The ETF Innovators Global Stem Cell and Regenerative Medicine Index includes 40 companies with market caps less than $1B at the index inception on 2/22/09 and the total market value of the index is down 7.6% at 3,629 from a starting value of 3,928. The index is down 26.3% over the past year on an equal-weight basis, compared to losses of 34.5% for the Healthcare Sector SPDR (XLV), 17.1% for iShares Nasdaq Biotech (IBB), 9.8% for SPDR S&P Biotech (XBI), 26.5% for PowerShares Biotech & Genome (PBE), and 43.4% for the S&P 500 SPDR (SPY). <> In the near-term, President Obama i...
|
Global Stem Cell and Regenerative Medicine Index
CYTX
|
|
|
-12.66%
in
4 days
(closed on 03/01/09)
By Mike Havrilla on 2/25/09
www.BioMedReports.com The ETF Innovators Global Stem Cell and Regenerative Medicine Index includes 40 companies with market caps less than $1B at the index inception and the total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09 and current value of 3,860 as of 2/25/09 - down 1.7% from the closing value last week. <> <> The index is down 23.8% over the past year on an equal-weight basis, compared to losses of 21.4% for the Heal...
|
Global Stem Cell Index Down 9% Last Week
CYTX
|
|
|
-2.17%
in
3 days
(closed on 02/25/09)
Global Stem Cell Index Down 9% Last Week By Mike Havrilla on 2/21/09 The ETF Innovators Global Stem Cell and Regenerative Medicine Index of 40 companies with market caps less than $1B at the index inception lost 9% of its value last week and is down 24.8% over the past year on an equal-weight basis, compared to losses of 21.6% for the Healthcare Sector SPDR (XLV), 8.4% for iShares Nasdaq Biotech (IBB), 4.5% for SPDR S&P Biotech (XBI), 19.9% for PowerShares Biotech & Genome (PBE), and 41.6% for the S&P 500 SPDR (SPY).
|
Global Stem Cell and Regenerative Medicine Index
CYTX
|
|
|
-21.22%
in
4 days
(closed on 02/22/09)
Global Stem Cell and Regenerative Medicine Index By Mike Havrilla on 2/17/09 <> The table at my website link below includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously . The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment...
|
People Bullish on CYTX
People Bearish on CYTX
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CYTX |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Cytori Therapeutics Inc
- Answers.com
